A phase 2 study reported early evidence that a triplet regimen combining regorafenib, chemotherapy, and nivolumab was safe and remodeled the tumor microenvironment in advanced gastric cancer, according to the provided trial update. The finding points to ongoing experimentation with checkpoint-based combinations designed to improve response depth in difficult-to-treat settings. Separately, researchers described a new molecular finding in lung cancer: the phase-separation protein PHLDB2 promotes lung adenocarcinoma progression through FLNA stabilization and ERK activation, identifying a potential new therapeutic vulnerability. Together, the items reflect two complementary directions in oncology: clinical strategies to reprogram the microenvironment and preclinical work that defines actionable signaling nodes.